Analysts expect a discussion on Bavarian Nordic's future direction to ensue
Sydbank keeps an eye out for signs in Bavarian’s upcoming financial statements of whether the company aims to keep up investments in drug development while acquiring technology and other companies.
by marketwire
Sales of travel vaccines and more orders for the coveted smallpox vaccine continue to boost Bavarian Nordic’s balance sheet, and the company is expected to maintain its guidance for the year when it presents its second-quarter results on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
